Optimal drug therapy for Staphylococcus aureus bacteraemia in adults.
Journal
Current opinion in critical care
ISSN: 1531-7072
Titre abrégé: Curr Opin Crit Care
Pays: United States
ID NLM: 9504454
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
medline:
11
9
2023
pubmed:
29
8
2023
entrez:
29
8
2023
Statut:
ppublish
Résumé
Staphylococcus aureus is a significant human pathogen, causing a variety of infections, from skin and soft tissue infections to endocarditis, bone and joint infections and deep tissue abscesses. Mortality from S. aureus bacteraemia remains high, without major therapeutic advances in recent decades. In recent years, optimized dosing of antibiotics is increasingly being recognized as a cornerstone of management for severe infections including S. aureus bacteraemia. This comprehensive review details the pharmacokinetics/pharmacodynamics (PK/PD) targets for commonly used antistaphylococcal antibiotics and the doses predicted to achieve them in clinical practice. Recent advances in dosing of teicoplanin and use of cefazolin in CNS infections and findings from combination therapy studies are discussed. Drug exposure relationships related to toxicity are also detailed. This review details the different PK/PD targets for drugs used to treat S. aureus bacteraemia and how to apply them in various scenarios. The drug doses that achieve them, and the risks of toxicity are also provided.
Identifiants
pubmed: 37641503
doi: 10.1097/MCC.0000000000001072
pii: 00075198-990000000-00098
doi:
Substances chimiques
Cefazolin
IHS69L0Y4T
Anti-Bacterial Agents
0
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
446-456Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Références
Tong SY, Davis JS, Eichenberger E, et al. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 2015; 28:603–661.
Verway M, Brown KA, Marchand-Austin A, et al. Prevalence and mortality associated with bloodstream organisms: a population-wide retrospective cohort study. J Clin Microbiol 2022; 60:e0242921.
Macneal WJ, Frisbee FC. One hundred patients with Staphylococcus septicemia receiving bacteriophage service. Am J Med Sci 1936; 191:179–195.
Skinner D, Keefer CS. Significance of bacteremia caused by Staphylococcus aureus : a study of one hundred and twenty-two cases and a review of the literature concerned with experimental infection in animals. Arch Intern Med 1941; 68:851–875.
Australian Commission on Safety and Quality in Healthcare (ACSQHC). AURA 2019: third Australian report on antimicrobial use and resistance in human health. Sydney: ACSQHC; 2019.
Austin ED, Sullivan SS, Macesic N, et al. Reduced mortality of Staphylococcus aureus bacteremia in a retrospective cohort study of 2139 patients: 2007–2015. Clin Infect Dis 2020; 70:1666–1674.
Bai AD, Lo CKL, Komorowski AS, et al. Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clin Microbiol Infect 2022; 28:1076–1084.
Tong SY, Nelson J, Paterson DL, et al. CAMERA2 – combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial. Trials 2016; 17:170.
Campbell AJ, Dotel R, Braddick M, et al. Clindamycin adjunctive therapy for severe Staphylococcus aureus treatment evaluation (CASSETTE)-an open-labelled pilot randomized controlled trial. JAC Antimicrob Resist 2022; 4:dlac014.
Cheng MP, Lawandi A, Butler-Laporte G, et al. Adjunctive daptomycin in the treatment of methicillin-susceptible Staphylococcus aureus bacteremia: a randomized, controlled trial. Clin Infect Dis 2021; 72:e196–e203.
Barequet IS, Bourla N, Pessach YN, et al. Staphylolysin is an effective therapeutic agent for Staphylococcus aureus experimental keratitis. Graefes Arch Clin Exp Ophthalmol 2012; 250:223–229.
Petrovic Fabijan A, Lin RCY, Ho J, et al. Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nat Microbiol 2020; 5:465–472.
Minichmayr IK, Aranzana-Climent V, Friberg LE. Pharmacokinetic/pharmacodynamic models for time courses of antibiotic effects. Int J Antimicrob Agents 2022; 60:106616.
Singh R, Almutairi M, Alm RA, et al. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model. J Antimicrob Chemother 2017; 72:2796–2803.
Salem AH, Zhanel GG, Ibrahim SA, Noreddin AM. Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus . Clin Exp Pharmacol Physiol 2014; 41:437–443.
Craig WA. Does the dose matter? Clin Infect Dis 2001; 33: (Suppl 3): S233–S237.
Drusano GL. Antimicrobial pharmacodynamics: critical interactions of ‘bug and drug’. Nat Rev Microbiol 2004; 2:289–300.
Wong G, Briscoe S, McWhinney B, et al. Therapeutic drug monitoring of beta-lactam antibiotics in the critically ill: direct measurement of unbound drug concentrations to achieve appropriate drug exposures. J Antimicrob Chemother 2018; 73:3087–3094.
Udy AA, Lipman J, Jarrett P, et al. Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance? Crit Care 2015; 19:28.
Tong SYC, Lye DC, Yahav D, et al. Effect of vancomycin or daptomycin with vs without an antistaphylococcal beta-lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA Bacteremia: A randomized clinical trial. JAMA 2020; 323:527–537.
Mattingly TJ 2nd, Meninger S, Heil EL. Penicillin skin testing in methicillin-sensitive Staphylococcus aureus bacteremia: a cost-effectiveness analysis. PLoS One 2019; 14:e0210271.
Karchmer AW. Combination therapy for methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: beauty remains in the eye of the beholder. Clin Infect Dis 2021; 72:1526–1528.
Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26:1–10. quiz 1–2.
Eagle H, Musselman AD. The slow recovery of bacteria from the toxic effects of penicillin. J Bacteriol 1949; 58:475–490.
Bigger J. Treatment of Staphylococcal infections with penicillin by intermittent sterilisation. Lancet 1944; 244:497–500.
Parker RF, Luse S. The action of penicillin on Staphylococcus : further observations on the effect of a short exposure. J Bacteriol 1948; 56:75–81.
McDonald PJ, Craig WA, Kunin CM. Persistent effect of antibiotics on Staphylococcus aureus after exposure for limited periods of time. J Infect Dis 1977; 135:217–223.
Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med 2020; 46:1127–1153.
Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65:1771–1778.
Carlier M, Roberts JA, Stove V, et al. A simulation study reveals lack of pharmacokinetic/pharmacodynamic target attainment in de-escalated antibiotic therapy in critically ill patients. Antimicrob Agents Chemother 2015; 59:4689–4694.
Jager NGL, van Hest RM, Xie J, et al. Optimization of flucloxacillin dosing regimens in critically ill patients using population pharmacokinetic modelling of total and unbound concentrations. J Antimicrob Chemother 2020; 75:2641–2649.
Calain P, Krause KH, Vaudaux P, et al. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections. J Infect Dis 1987; 155:187–191.
Wilkes S, van Berlo I, Ten Oever J, et al. Population pharmacokinetic modelling of total and unbound flucloxacillin in noncritically ill patients to devise a rational continuous dosing regimen. Int J Antimicrob Agents 2019; 53:310–317.
Courjon J, Garzaro M, Roger PM, et al. A population pharmacokinetic analysis of continuous infusion of cloxacillin during Staphylococcus aureus bone and joint infections. Antimicrob Agents Chemother 2020; 64:e01562-20.
Turnidge J, Grayson ML. Optimum treatment of staphylococcal infections. Drugs 1993; 45:353–366.
Murinova I, Svidrnoch M, Gucky T, et al. Population pharmacokinetic analysis proves superiority of continuous infusion in PK/PD target attainment with oxacillin in Staphylococcal infections. Antibiotics (Basel) 2022; 11:1736.
Housman ST, Sutherland CA, Nicolau DP. Pharmacodynamic profile of commonly utilised parenteral therapies against meticillin-susceptible and meticillin-resistant Staphylococcus aureus collected from US hospitals. Int J Antimicrob Agents 2014; 44:235–241.
Imani S, Buscher H, Marriott D, et al. Too much of a good thing: a retrospective study of beta-lactam concentration-toxicity relationships. J Antimicrob Chemother 2017; 72:2891–2897.
Benefield RJ, Barker BC, Gast CM, Alexander DP. Patient variables associated with nafcillin plasma concentrations and toxicity. Pharmacotherapy 2016; 36:994–1002.
Moser S, Rehm S, Guertler N, et al. Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs. J Antimicrob Chemother 2021; 76:1845–1854.
Meenks SD, Punt N, le Noble J, et al. Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study. Crit Care 2023; 27:82.
Zelenitsky SA, Beahm NP, Iacovides H, et al. Limitations of ceftriaxone compared with cefazolin against MSSA: an integrated pharmacodynamic analysis. J Antimicrob Chemother 2018; 73:1888–1894.
Vogelman B, Gudmundsson S, Leggett J, et al. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158:831–847.
MacGowan AP, Noel AR, Tomaselli S, Bowker KE. Pharmacodynamics of ceftaroline against Staphylococcus aureus studied in an in vitro pharmacokinetic model of infection. Antimicrob Agents Chemother 2013; 57:2451–2456.
Roberts JA, Udy AA, Jarrett P, et al. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in posttrauma critically ill patients. J Antimicrob Chemother 2015; 70:1495–1502.
Bellouard R, Deschanvres C, Deslandes G, et al. Population pharmacokinetic study of cefazolin dosage adaptation in bacteremia and infective endocarditis based on a nomogram. Antimicrob Agents Chemother 2019; 63:e00806-19.
So W, Kuti JL, Nicolau DP. Population pharmacokinetics of cefazolin in serum and tissue for patients with complicated skin and soft tissue infections (cSSTI). Infect Dis Ther 2014; 3:269–279.
Nannini EC, Stryjewski ME, Singh KV, et al. Inoculum effect with cefazolin among clinical isolates of methicillin-susceptible Staphylococcus aureus : frequency and possible cause of cefazolin treatment failure. Antimicrob Agents Chemother 2009; 53:3437–3441.
Antosz K, Battle S, Chang J, et al. Cefazolin in the treatment of central nervous system infections: a narrative review and recommendation. Pharmacotherapy 2023; 43:85–95.
Bai AD, Findlater A, Irfan N, et al. Cefazolin versus cloxacillin as definitive antibiotic therapy for methicillin-susceptible Staphylococcus aureus spinal epidural abscess: a retrospective cohort study. Int J Antimicrob Agents 2021; 58:106429.
Novak AR, Krsak M, Kiser TH, et al. Pharmacokinetic evaluation of cefazolin in the cerebrospinal fluid of critically ill patients. Open Forum Infect Dis 2022; 9:ofab649.
Helfer VE, Zavascki AP, Zeitlinger M, et al. Population pharmacokinetic modeling and probability of target attainment of ceftaroline in brain and soft tissues. Antimicrob Agents Chemother 2022; 66:e0074122.
Holland TL, Doernberg CS, Pavlov SB, et al. Ceftobiprole compared to daptomycin with or without optional aztreonam for the treatment of complicated Staphylococcus aureus (SAB): results of a phase 3, randomized, double-blind trial (ERADICATE). Open Forum Infect Dis 2022; 9: ofac492.1892.
Hamed K, Engelhardt M, Jones ME, et al. Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial. Future Microbiol 2020; 15:35–48.
Barreto EF, Webb AJ, Pais GM, et al. Setting the beta-lactam therapeutic range for critically ill patients: is there a floor or even a ceiling? Crit Care Explor 2021; 3:e0446.
Legg A, Meagher N, Johnson SA, et al. Risk factors for nephrotoxicity in methicillin-resistant Staphylococcus aureus bacteraemia: a post hoc analysis of the CAMERA2 trial. Clin Drug Investig 2022; 43:23–33.
Sullivan EL, Turner RB, O’Neal HR Jr, Crum-Cianflone NF. Ceftaroline-associated neutropenia: case series and literature review of incidence, risk factors, and outcomes. Open Forum Infect Dis 2019; 6:ofz168.
Riccobene TA, Carrothers TJ, Knebel W, et al. Pharmacokinetic and pharmacodynamic target attainment in adult and pediatric patients following administration of ceftaroline fosamil as a 5-minute infusion. Clin Pharmacol Drug Dev 2021; 10:420–427.
Cristinacce A, Wright JG, Macpherson M, et al. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models. Diagn Microbiol Infect Dis 2021; 99:115292.
Cristinacce A, Wright JG, Stone GG, et al. A retrospective analysis of probability of target attainment in community-acquired pneumonia: ceftaroline fosamil versus comparators. Infect Dis Ther 2019; 8:185–198.
Van Wart SA, Ambrose PG, Rubino CM, et al. Pharmacokinetic-pharmacodynamic target attainment analyses to evaluate in vitro susceptibility test interpretive criteria for ceftaroline against Staphylococcus aureus and Streptococcus pneumoniae . Antimicrob Agents Chemother 2014; 58:885–891.
Blumenthal KG, Parker RA, Shenoy ES, Walensky RP. Improving clinical outcomes in patients with methicillin-sensitive Staphylococcus aureus bacteremia and reported penicillin allergy. Clin Infect Dis 2015; 61:741–749.
Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 2020; 77:835–864.
Hagihara M, Umemura T, Kimura M, et al. Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus . J Infect Chemother 2012; 18:10–16.
Ramos-Martin V, Johnson A, McEntee L, et al. Pharmacodynamics of teicoplanin against MRSA. J Antimicrob Chemother 2017; 72:3382–3389.
Haseeb A, Alqurashi MK, Althaqafi AS, et al. A systematic review on clinical safety and efficacy of vancomycin loading dose in critically ill patients. Antibiotics (Basel) 2022; 11:409.
Flannery AH, Bissell BD, Bastin MT, et al. Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis. Crit Care Med 2020; 48:912–918.
Wilson AP, Gruneberg RN, Neu H. A critical review of the dosage of teicoplanin in Europe and the USA. Int J Antimicrob Agents 1994; 4: (Suppl 1): 1–30.
Hanai Y, Takahashi Y, Niwa T, et al. Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. J Antimicrob Chemother 2022; 77:869–879.
Hanai Y, Takahashi Y, Niwa T, et al. Optimal trough concentration of teicoplanin for the treatment of methicillin-resistant Staphylococcus aureus infection: a systematic review and meta-analysis. J Clin Pharm Ther 2021; 46:622–632.
Lodise TP, Patel N, Lomaestro BM, et al. Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. Clin Infect Dis 2009; 49:507–514.
Lodise TP, Drusano G. Vancomycin area under the curve-guided dosing and monitoring for adult and pediatric patients with suspected or documented serious methicillin-resistant Staphylococcus aureus infections: putting the safety of our patients first. Clin Infect Dis 2021; 72:1497–1501.
Finch NA, Zasowski EJ, Murray KP, et al. A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity. Antimicrob Agents Chemother 2017; 61:e01293-17.
Nix DE, Davis LE, Matthias KR. The relationship of vancomycin 24-h AUC and trough concentration. Am J Health Syst Pharm 2022; 79:534–539.
Khatib R, Sharma M, Johnson LB, et al. Decreasing prevalence of isolates with vancomycin heteroresistance and vancomycin minimum inhibitory concentrations >/=2 mg/L in methicillin-resistant Staphylococcus aureus over 11 years: potential impact of vancomycin treatment guidelines. Diagn Microbiol Infect Dis 2015; 82:245–248.
Shariati A, Dadashi M, Moghadam MT, et al. Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis. Sci Rep 2020; 10:12689.
Avedissian SN, Pais GM, O’Donnell JN, et al. Twenty-four hour pharmacokinetic relationships for intravenous vancomycin and novel urinary biomarkers of acute kidney injury in a rat model. J Antimicrob Chemother 2019; 74:2326–2334.
Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis 2008; 8:53–66.
Shorr AF, Kunkel MJ, Kollef M. Linezolid versus vancomycin for Staphylococcus aureus bacteraemia: pooled analysis of randomized studies. J Antimicrob Chemother 2005; 56:923–929.
Brown NM, Brown EM, Guideline Development G. Treatment of methicillin-resistant Staphylococcus aureus (MRSA): updated guidelines from the UK. J Antimicrob Chemother 2021; 76:1377–1378.
Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18–e55.
Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42:1411–1423.
Heidari S, Khalili H. Linezolid pharmacokinetics: a systematic review for the best clinical practice. Eur J Clin Pharmacol 2023; 79:195–206.
Whitehouse T, Cepeda JA, Shulman R, et al. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill. J Antimicrob Chemother 2005; 55:333–340.
Adembri C, Fallani S, Cassetta MI, et al. Linezolid pharmacokinetic/pharmacodynamic profile in critically ill septic patients: intermittent versus continuous infusion. Int J Antimicrob Agents 2008; 31:122–129.
Tsuji BT, Brown T, Parasrampuria R, et al. Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus . Antimicrob Agents Chemother 2012; 56:3712–3719.
Shi C, Xia J, Ye J, et al. Effect of renal function on the risk of thrombocytopaenia in patients receiving linezolid therapy: a systematic review and meta-analysis. Br J Clin Pharmacol 2022; 88:464–475.
Chen CC, Liu WT, Lin SH. Lactic acidosis associated with standard dose linezolid in a kidney recipient with impaired renal function. Braz J Infect Dis 2022; 26:101701.
Tsuji Y, Holford NHG, Kasai H, et al. Population pharmacokinetics and pharmacodynamics of linezolid-induced thrombocytopenia in hospitalized patients. Br J Clin Pharmacol 2017; 83:1758–1772.
Lau C, Marriott D, Bui J, et al. LInezolid Monitoring to MInimise Toxicity (LIMMIT1): a multicentre retrospective review of patients receiving linezolid therapy and the impact of therapeutic drug monitoring. Int J Antimicrob Agents 2023; 61:106783.
Tsuji Y, Hiraki Y, Matsumoto K, et al. Thrombocytopenia and anemia caused by a persistent high linezolid concentration in patients with renal dysfunction. J Infect Chemother 2011; 17:70–75.
Bishop E, Melvani S, Howden BP, et al. Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients. Antimicrob Agents Chemother 2006; 50:1599–1602.
Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus . N Engl J Med 2006; 355:653–665.
Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus : subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 2008; 62:1413–1421.
D’Avolio A, Pensi D, Baietto L, et al. Daptomycin pharmacokinetics and pharmacodynamics in septic and critically ill patients. Drugs 2016; 76:1161–1174.
Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63–68.
Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57:1568–1576.
Butterfield-Cowper JM, Lodise TP Jr, Pai MP. A fixed versus weight-based dosing strategy of daptomycin may improve safety in obese adults. Pharmacotherapy 2018; 38:981–985.
Bhavnani SM, Rubino CM, Ambrose PG, Drusano GL. Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: data from a randomized trial of patients with bacteremia and endocarditis. Clin Infect Dis 2010; 50:1568–1574.
Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948–2953.
Eisenstein BI, Oleson FB Jr, Baltz RH. Daptomycin: from the mountain to the clinic, with essential help from Francis Tally, MD. Clin Infect Dis 2010; 50: (Suppl 1): S10–S15.
Paul M, Bishara J, Yahav D, et al. Trimethoprim-sulfamethoxazole versus vancomycin for severe infections caused by methicillin resistant Staphylococcus aureus : randomised controlled trial. BMJ 2015; 350:h2219.
Tong SYC, Mora J, Bowen AC, et al. The Staphylococcus aureus network Adaptive Platform trial protocol: new tools for an old foe. Clin Infect Dis 2022; 75:2027–2034.
Molina KC, Lunowa C, Lebin M, et al. Comparison of sequential dalbavancin with standard-of-care treatment for Staphylococcus aureus bloodstream infections. Open Forum Infect Dis 2022; 9:ofac335.
Holubar M, Meng L, Alegria W, Deresinski S. Bacteremia due to methicillin-resistant Staphylococcus aureus : an update on new therapeutic approaches. Infect Dis Clin North Am 2020; 34:849–861.
Davis JS, Sud A, O'Sullivan MVN, et al. Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis 2016; 62:173–180.
Pujol M, Miro JM, Shaw E, et al. Daptomycin plus fosfomycin versus daptomycin alone for methicillin-resistant Staphylococcus aureus bacteremia and endocarditis: a randomized clinical trial. Clin Infect Dis 2021; 72:1517–1525.
Thwaites GE, Scarborough M, Szubert A, et al. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 2018; 391:668–678.